Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Completed clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
2343
Shown on this page
12
Current sort
Recently updated
Status scope
Completed
Additional filters apply within this recruitment status.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this status page

These controls apply only within Completed. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 553–564 of 2,343 matching trials with status Completed.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search
Completed Phase 2 Interventional Results available

Combination Immunotherapy in Colorectal Cancer

NCT05571293
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Balstilimab, Botensilimab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Brooklyn, New York • Flushing, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 3:04 AM EDT
Completed No phase listed Observational

Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI

NCT05565313
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Not listed
Lead sponsor
Maastricht Radiation Oncology
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 4, 2026, 5:54 AM EST
Completed Phase 1 Interventional

F-Tryptophan PET/CT in Human Cancers

NCT05556473
View directory record Official record
Conditions
Breast Cancer, Intracranial Glioma, Metastatic Brain Tumor, Neuroendocrine Tumors, Rectal Cancer
Interventions
1-(2-[18F]FLUOROETHYL)-L-Tryptophan
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 6:02 PM EDT
Completed Phase 1 Interventional

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

NCT05479812
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
WTX-124, pembrolizumab
Drug
Lead sponsor
Werewolf Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 7:46 AM EDT
Completed Phase 1Phase 2 Interventional

NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

NCT05023486
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor Malignancies
Interventions
Anti-PD-1 Therapy, NP-G2-044 Combination therapy, NP-G2-044 Monotherapy
Drug
Lead sponsor
Novita Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 11:17 AM EDT
Completed Phase 3 Interventional

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

NCT04652882
View directory record Official record
Conditions
Chronobiology Disorders, Sleep Disorders, Circadian Rhythm, Sleep Wake Disorders
Interventions
Placebo, Tasimelteon
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Redwood City, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 5:29 AM EDT
Completed No phase listed Observational

Patient-Centered Assessment of Symptoms and Outcomes

NCT03952624
View directory record Official record
Conditions
CFS, Cancer, Fatigue, Lupus, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Sjogrens, Systemic Lupus Erthematosus
Interventions
Not listed
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 8:12 PM EDT
Completed Not applicable Interventional

Remote Alcohol Monitoring to Facilitate Abstinence From Alcohol: Exp 1

NCT03883126
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Mikhail N Koffarnus
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Lexington, Kentucky • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 12:16 AM EDT
Completed Early Phase 1 Interventional

Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder

NCT03748446
View directory record Official record
Conditions
Bipolar Depression, Major Depressive Disorder
Interventions
Nitrogen gas, Xenon
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

NCT03194893
View directory record Official record
Conditions
Neoplasms
Interventions
Alectinib, Crizotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 1:11 PM EDT
Completed Phase 2 Interventional Results available

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

NCT03179904
View directory record Official record
Conditions
Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, HER2-positive Breast Cancer
Interventions
Anastrozole, Biopsy, Biospecimen Collection, Computed Tomography, Denifanstat, Echocardiography, Exemestane, Fulvestrant, Letrozole, Magnetic Resonance Imaging, Paclitaxel, Trastuzumab
Drug · Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 15, 2026, 9:58 PM EDT
Completed Not applicable Interventional

Behavioral and Functional Task Development, Implementation, and Testing

NCT02108054
View directory record Official record
Conditions
Addiction, Alcohol Dependence, Alcohol Drinking, Alcohol Use Disorder, Alcoholism
Interventions
7T MRI
Device
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 4:30 AM EDT